Drew M. Pardoll, MD, PhD Receives Funding for MANAFEST Project
NEW YORK, NY – The Mark Foundation for Cancer Research, a New York-based non-profit organization that funds groundbreaking cancer research, announces its first multi-institutional collaborative grant to Drew Pardoll, MD, PhD, Director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Co-Director of the Cancer Immunology Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.
This three-year, $3 million award supports the MANAFEST project which aims to standardize approaches for identifying optimal cancer neoantigens and integrating immunophenotyped and immuno-oncology information with existing cancer genomic data.
A world-renowned cancer research scientist, Dr. Pardoll leads this project in collaboration with co-investigator, Alexander Baras, MD, PhD of Johns Hopkins Medicine; Harlan Robins, PhD of Fred Hutchinson Cancer Research Center; and Adaptive Biotechnologies. Dr. Pardoll’s team will also have access to the extensive data previously established by Memorial Sloan Kettering Cancer Center’s cBioPortal for Cancer Genomics.
“The MANAFEST Project is in direct alignment with The Mark Foundation’s mission to be a premier partner to the world’s most innovative cancer researchers,” said Michele Cleary, PhD, Chief Executive Officer of The Mark Foundation. “Drew has assembled a strong team of scientific collaborators, giving us every confidence that the outcomes from this project will have a great impact on the field of immuno-oncology.”
# # #
The Mark Foundation for Cancer Research funds groundbreaking research integrating discoveries in biology with innovative technology to deliver breakthroughs to patients. Established in 2015, The Mark Foundation serves as a premier partner to cancer researchers through an exemplary non-profit business model that combines the funding of high-impact, transformative basic and translational cancer research with venture philanthropy. To learn more about the work of The Mark Foundation for Cancer Research, visit: https://mark.test